Aeglea BioTherapeutics announced the appointment of Jeffrey Goldberg as president, CEO and member of the board of directors effective November 29. Goldberg is an accomplished biotech executive with over 25 years of experience leading teams from preclinical discovery through commercialization and previously served as president and CEO of Immunitas Therapeutics.
Published first on TheFly
